Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
currently at $4.96. trying to break through
$5.00. 6,268,039 share volume.
has held at the $4.35 level from last night.
i don't expect much movement
Only reason it's not moving is because the only people trading in and out of arna is the short sellers. All the major holders aren't selling
the 1.56billion in one-time purchase price
adjustment payments, is a " game changer."
esai must have a lot of confidence in their
ability to sale belviq, and know what the demand
is for it.
missed it. went to the bathroom. what
did they say
Post Unavailable
Additional Information
Arena lung drug trial experiences heart problem 08/29 08:27 AM
Arena plans Phase II trial of hypertension drug • 9:50 AM
Arena Pharmaceuticals (ARNA -0.6%) completes the Phase 1b trial of its APD811 oral treatment for pulmonary arterial hypertension.
During the study, which involved 40 healthy volunteers, no serious adverse events were observed, although the most frequent side effects were headache, nausea and jaw pain.
The company plans to start Phase 2 testing for APD811 in Q1 2014. (PR)
News for 'ARNA' - (Arena Pharmaceuticals Completes Phase 1b Clinical Trial Evaluating APD811 for Pulmonary Arterial Hypertension Preparation for APD811 Phase 2 Clinical Trial Now Underway --)
SAN DIEGO, Aug. 28, 2013 /PRNewswire via COMTEX/ -- Arena Pharmaceuticals, Inc.
(NASDAQ: ARNA) today announced the completion of a Phase 1b clinical trial for
APD811, an investigational oral prostacyclin (IP) receptor agonist intended for
the treatment of pulmonary arterial hypertension (PAH). The company plans to
initiate a Phase 2 clinical trial for APD811 in the first quarter of 2014.
Arena Sales Pace 10 Weeks In
Aug 23 2013, 11:50 | by Spencer Osborne | about:ARNA
include:ESALY.PK
If you follow Arena Pharmaceuticals (ARNA), you are well aware that the perceived value in the company is tied to the anti-obesity drug Belviq. While the company does indeed have a pipeline of other drugs, the viability of the company has, like it or not, been linked to Belviq. Because of this, weekly sales figures are closely monitored by long term investors and active traders alike. In my opinion there is a lot of potential upside in the prescription anti-obesity space, but it will take time to develop and come to fruition. The biggest challenges are cost, insurance reimbursement and general acceptance by physicians and consumers.
The weekly prescription sales figures are geared more toward active traders, of which Arena has many. Longer term investors take the weekly sales to try to establish a trend line and determine the potential of the company, or at least estimate when the potential can be realized. It has long been my opinion that we need to see 12 to 16 weeks of data to properly assess the sales through the end of the year and beyond. With 3 to 4 months of data we can begin to recognize the pace of growth and see how prescription refills are tracking. Part of the success of a drug is in seeing patients get a positive response and refilling their prescription. Before moving on to the numbers this week, I have my usual qualifiers in place:
· The data used is from IMS Healthcare (orange). This company reports numbers each Friday.
· I adjust the IMS data up 30% to account for any under-estimates that can arise for a number of reasons.
· Another company, Symphony Health, also tracks sales data. It typically comes out later in the day, and after the sales data from IMS has carried its impact on the markets. I track Symphony data, and I adjust it up by 20%. I am adding a Symphony data line (in green), though it will be 1 week trailing due to the timing (unless Symphony releases prior to submission of the article).
· The tracking blue path is a model on how Eisai (ESALY.PK) can arrive at $150 million in gross sales by the end of the year. More realistically, in my opinion, sales are pacing toward between $60 million and $70 million (gross) by the end of 2013 and the $150 million goal will not be met. Analysts like Leerink Swan and Jefferies (yellow line) are likely in the right neighborhood on their respective gross sales expectations. It is important to understand that gross sales is the sales number prior to discounts and adjustments. The blue lines track Eisai's "hopeful aspirations" goal, not Arena's goals.
· The charts have an "analysts' expectations" line (depicted in Yellow). This line now tracks to $68 million in gross sales by the end of the year. In theory, $68 million in gross sales will pay out about $10 million in "royalties" (percentage of net sales) to Arena. I use an average net script price of $100 (down from $125). In the most recent quarter the average was $82. I am adjusting upward because the weight of free trials should improve as the next 6 months pass. The analyst line represents what sales would have to track to get to the $12 price target that they have established.
Belviq bests Qsymia in weekly scripts
5 MINUTES AGOARNA, VVUS
TRx and NRx for Belviq (ARNA) were up 10% and 9% last week respectively, outstripping Qsymia (VVUS) TRx and NRx growth of 7% and 6%.
2.4ishi might be the bottom again
Vivus, Arena post strong gains • 2:03 PM
Weight-loss drugmakers Arena Pharmaceuticals (ARNA +3.2%) and Vivus (VVUS +3.1%) are enjoying a strong session.
Both stocks had fallen for three consecutive days.
Weekly scripts data from IMS shows Qsymia TRx +10% and Belviq TRx -1% for the week ended 08/09.
For more on ARNA see SA contributor Spencer Osborne's latest article and a BioPharm Insight piece reprinted by FT which outlines the company's plans to study Belviq in combination with phentermine.
Next 6 weeks will be lower lows market wide is what I'm hearin
All Eyes Awaiting Arena Prescription Numbers
Aug 15 2013, 12:51 | by Spencer Osborne | about:ARNA
include:VVUS
The tug-of-war in the stock price of Arena Pharmaceuticals (ARNA) continues this week. The price movement shows the appearance of a run getting ready to start, but the bears then seem to step in and bring the equity back down. The biggest difference in the past week or so is that Arena is now seeing the battleground take place in the $7's rather than the $6's. The next catalyst for Arena happens tomorrow when the prescription numbers from IMS Health are released in the morning, followed by the Symphony Health numbers later in the afternoon. Savvy investors will be placing their proverbial bets today. Make no mistake, this is an active equity with near term action playing on the volatility that Arena offers.
Meanwhile, long term investors are betting on the potential of not only the weight loss drug Belviq, but the other indications that Belviq could treat, as well as the Arena pipeline. The chart below illustrates both IMS (orange) and Symphony (green) numbers vs. a model tracking to $150 in gross sales (BLUE) and analyst expectations that would deliver $10 million in "royalty" revenue (percentage of the net sales) to Arena. At $10 million in "royalty revenue some analysts carry a $12 price target on Arena.
(click to enlarge)
While there has been much debate about IMS numbers vs. Symphony numbers, the two are tracking in the exact same area. In fact, the difference between the two numbers, when adjusted, equates to about 5 days of scripts. Thus far, sales of Belviq have been good but not great. They have shown traction, but are not rocketing upward. Simply stated, this is a process that will not happen overnight. This is especially true given the dynamics at play when we look at the weight-loss space:
Prescription weight-loss drugs still contend with the fen-phen fiasco because the drug was promptly removed from the market due to heart issues
Insurance companies are still hesitant to cover anti-obesity drugs. This dynamic is changing, but will take time
The cost of treatment, especially for uninsured can be daunting, at least in perception, to many people
It takes time to get doctors on board and educate them about the benefits of the drug.
As yet there is no direct to consumer advertising
It takes time to get enough people with good results to begin a more organic word-of-mouth movement.
Tech Investor
Seeking Alpha
The chart depicted above shows results through last week. Whether you prefer IMS numbers or Symphony matters little. As stated, they are in the same vicinity in terms of sales traction and trending. What moves the needle on Arena when it comes to sales figures is IMS Health numbers. They come out first and the market reacts. Symphony numbers can track about 6 hours later, after the moves have already played out. This past week Symphony numbers did not come out until Monday, three days after IMS.
As stated, neither the IMS or Symphony numbers are illustrating a blistering pace. They are however tracking above the level of sales that would, in theory, give Arena a $12 price target. For long term holders that represents a more than 50% increase from current equity prices. That is not a bad return, even for the more active near term trader.
The interesting dynamic here is that we are only a 4 to 6 weeks away from being able to extrapolate sales to a point where the potential exists that near term and long term investors goals may align. If that happens, equity appreciation may not be far behind. If the trend line demonstrates that the sales will get to levels deserving of a higher price target, the tug-of-war may fade away.
Specific to tomorrows numbers, we want to see the sales come in high enough to remain above the yellow analysts line, at a minimum, and preferably remaining above the blue $150 million dollar line (gross sales). For comparison, the analyst line tracks to about $70 million in gross sales.
If IMS numbers come in at about 3,500 it will represent growth, but not offer anything very compelling to shift the stock price upward in reaction. To see a swing upward in reaction it would take an IMS number of 4,000 or more. In my opinion, we will not see that happen yet. Essentially we are now approaching the time where patients will begin to arrive at the 12 week decision point of whether or not Belviq works for them. Those that respond to the drug would, in theory, remain on it. Those that do not respond will come off. What we want to see is enough growth in new patients to not only offset the churn of non-responders, but also demonstrate positive growth overall.
Competitor Vivus (VVUS), with its drug Qsymia, has shown a choppy path in sales. This is attributable to many factors, one of which is patient churn. It creates flat spots in the growth curve of Qsymia sales. What near term traders are looking for is whether flat spots develop in Belviq sales. If sales appear to flatten out, the active traders will rule the day once again. If the sales show continued growth, the philosophy of the buy-and-holders will gain strength.
IMS numbers should be out by mid-morning on Friday. Be ready, because it is getting interesting. Stay Tuned.
Disclosure: I am long ARNA. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
All Eyes Awaiting Arena Prescription Numbers
Aug 15 2013, 12:51 | by Spencer Osborne | about:ARNA
include:VVUS
The tug-of-war in the stock price of Arena Pharmaceuticals (ARNA) continues this week. The price movement shows the appearance of a run getting ready to start, but the bears then seem to step in and bring the equity back down. The biggest difference in the past week or so is that Arena is now seeing the battleground take place in the $7's rather than the $6's. The next catalyst for Arena happens tomorrow when the prescription numbers from IMS Health are released in the morning, followed by the Symphony Health numbers later in the afternoon. Savvy investors will be placing their proverbial bets today. Make no mistake, this is an active equity with near term action playing on the volatility that Arena offers.
Meanwhile, long term investors are betting on the potential of not only the weight loss drug Belviq, but the other indications that Belviq could treat, as well as the Arena pipeline. The chart below illustrates both IMS (orange) and Symphony (green) numbers vs. a model tracking to $150 in gross sales (BLUE) and analyst expectations that would deliver $10 million in "royalty" revenue (percentage of the net sales) to Arena. At $10 million in "royalty revenue some analysts carry a $12 price target on Arena.
(click to enlarge)
While there has been much debate about IMS numbers vs. Symphony numbers, the two are tracking in the exact same area. In fact, the difference between the two numbers, when adjusted, equates to about 5 days of scripts. Thus far, sales of Belviq have been good but not great. They have shown traction, but are not rocketing upward. Simply stated, this is a process that will not happen overnight. This is especially true given the dynamics at play when we look at the weight-loss space:
Prescription weight-loss drugs still contend with the fen-phen fiasco because the drug was promptly removed from the market due to heart issues
Insurance companies are still hesitant to cover anti-obesity drugs. This dynamic is changing, but will take time
The cost of treatment, especially for uninsured can be daunting, at least in perception, to many people
It takes time to get doctors on board and educate them about the benefits of the drug.
As yet there is no direct to consumer advertising
It takes time to get enough people with good results to begin a more organic word-of-mouth movement.
Tech Investor
Seeking Alpha
The chart depicted above shows results through last week. Whether you prefer IMS numbers or Symphony matters little. As stated, they are in the same vicinity in terms of sales traction and trending. What moves the needle on Arena when it comes to sales figures is IMS Health numbers. They come out first and the market reacts. Symphony numbers can track about 6 hours later, after the moves have already played out. This past week Symphony numbers did not come out until Monday, three days after IMS.
As stated, neither the IMS or Symphony numbers are illustrating a blistering pace. They are however tracking above the level of sales that would, in theory, give Arena a $12 price target. For long term holders that represents a more than 50% increase from current equity prices. That is not a bad return, even for the more active near term trader.
The interesting dynamic here is that we are only a 4 to 6 weeks away from being able to extrapolate sales to a point where the potential exists that near term and long term investors goals may align. If that happens, equity appreciation may not be far behind. If the trend line demonstrates that the sales will get to levels deserving of a higher price target, the tug-of-war may fade away.
Specific to tomorrows numbers, we want to see the sales come in high enough to remain above the yellow analysts line, at a minimum, and preferably remaining above the blue $150 million dollar line (gross sales). For comparison, the analyst line tracks to about $70 million in gross sales.
If IMS numbers come in at about 3,500 it will represent growth, but not offer anything very compelling to shift the stock price upward in reaction. To see a swing upward in reaction it would take an IMS number of 4,000 or more. In my opinion, we will not see that happen yet. Essentially we are now approaching the time where patients will begin to arrive at the 12 week decision point of whether or not Belviq works for them. Those that respond to the drug would, in theory, remain on it. Those that do not respond will come off. What we want to see is enough growth in new patients to not only offset the churn of non-responders, but also demonstrate positive growth overall.
Competitor Vivus (VVUS), with its drug Qsymia, has shown a choppy path in sales. This is attributable to many factors, one of which is patient churn. It creates flat spots in the growth curve of Qsymia sales. What near term traders are looking for is whether flat spots develop in Belviq sales. If sales appear to flatten out, the active traders will rule the day once again. If the sales show continued growth, the philosophy of the buy-and-holders will gain strength.
IMS numbers should be out by mid-morning on Friday. Be ready, because it is getting interesting. Stay Tuned.
Disclosure: I am long ARNA. I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it (other than from Seeking Alpha). I have no business relationship with any company whose stock is mentioned in this article.
Arena Approaches 50% Institutional Ownership
Aug 15 2013, 12:08 | by Spencer Osborne | about:ARNA
includes:OREX, VVUS
Arena Pharmaceuticals (ARNA) is approaching 50% institutional ownership. The company currently sits just below the magic number at 49% according to data recently updated by Nasdaq, and through June 30th of this year. Because the data is trailing, the company could already be over the 50% mark. We will not know that for a few more months.
Arena Approaches 50% Institutional Ownership
Aug 15 2013, 12:08 | by Spencer Osborne | about:ARNA
includes:OREX, VVUS
Arena Pharmaceuticals (ARNA) is approaching 50% institutional ownership. The company currently sits just below the magic number at 49% according to data recently updated by Nasdaq, and through June 30th of this year. Because the data is trailing, the company could already be over the 50% mark. We will not know that for a few more months.
News for 'ZNGA' - (Zynga Restructures Management)
Aug 15, 2013 (Zacks.com via COMTEX) -- The recently appointed Chief Executive
Officer of the social gaming company Zynga Inc. (ZNGA), Don Mattrick, is in the
process of restructuring the company's management hierarchy. This process, while
reducing the layers of hierarchy, is expected to increase management's
efficiency. Zynga recently announced that the Chief Operations Officer, David
Ko, Chief People Officer, Colleen McCreary, and Chief Technology Officer, Cadir
Mattrick cleans house: Zynga COO, CTO, HR chief reportedly leaving
Tue, Aug 13 · ZNGA
Sources tell AllThingsD Zynga (ZNGA) COO David Ko, CTO Cadir Lee, and Chief People Officer (i.e. HR chief) Colleen McCreary "will step down from their positions" as part of a restructuring launched by new CEO Don Mattrick.
Insider finance officer sold at 3
Zynga Inc (NASDAQ:ZNGA): By the end of last trading, Zynga (NASDAQ:ZNGA) shares
earned US$0.02 (or 0.70%) to US$2.87 with about 19.99 million shares exchanging
hands for the session, compared to its average volume of 29.11 million shares.
Pennystocksinsiders.com found company Chief Revenue Officer, Barry L. Cottle,
sold his shares at a price of US$3.00 on August 5. Want to know when company
insiders will buy or sell their shares? Want to monitor this company on an
on-going basis?
Read Full Report: http://www.Pennystocksinsiders.com/PR/080913A/ZNGA/Zynga.pdf
Cdub. can't have a buy, without a sale. but
by watching the " bid book," you can differentiate
between the amount of shares wanting to be
purchased. if the demand to purchase is high,
the price goes up due to the sell side knowing
that they will be able to get their sale price
because of that demand
more buy percentage than sell
Will add more below 2.40
Amen. Ichy cloud with bulging bolliger waist
Helluva consolidated bottom IMO up over the time grind now
FB has absolutely no need for pincus. He left a bad taste in their mouth and they are still spitting pincus out
Must watch. Weeee
http://search.yahoo.com/mobile/s?rewrite=72&.tsrc=apple&first=1&p=geico+pig+wee+commercial&pintl=en&pcarrier=AT%26T&pmcc=310&pmnc=410&fr=onesearch&nocache=1
the early bird catches the worm but the 2nd mouse gets the cheese
..::K3VIN::..
Shorts trying everything possible to keep it down fur sur
Yesterday, 09:41 PM ET
Report: 3 more Zynga execs head for exit
Sources tell Bloomberg Zynga (ZNGA) games SVP John Osvald, games VP Nathan Etter, and casino games chief Jesse Janosav have left the company since Don Mattrick was named CEO.
Needs a defibrillator , clear!!! ZAPP
CLEAR!!! ZZZAAAPPP
Needs a defibrillator , clear!!! ZAPP
CLEAR!!! ZZZAAAPPP
Needs a defibrillator , clear!!! ZAPP
CLEAR!!! ZZZAAAPPP
Jiff. Great job. Stay focused and keep on truckin
he is going to sell the ship
News for 'ARNA' - (Arena Pharmaceuticals Sets Date to Host Corporate Update and Financial Results Conference Call and Webcast)
Jul 29, 2013 (Close-Up Media via COMTEX) -- Arena Pharmaceuticals, Inc.
announced that it will provide a corporate update and report second quarter 2013
financial results before the NASDAQ Global Select Market opens on August 1.
According to a release, that same morning, Arena will host a conference call and
webcast at 8:30 a.m. Eastern Time (5:30 a.m. Pacific Time).
The conference call may be accessed by dialing 877.643.7155 for domestic callers
and 914.495.8552 for international callers. Please specify to the operator that
you would like to join the "Arena Pharmaceuticals' Second Quarter 2013 Financial
Results Call." The conference call will be webcast live under the investor
relations section of Arena's website, and will be archived there for 30 days
following the call. Please connect to Arena's website several minutes prior to
the start of the broadcast to ensure adequate time for any software download
News for 'ESALY' - (Eisai Announces Availability of Halaven(R) (eribulin) in Kuwait)
HATFIELD, England, Jul 28, 2013 (PR Newswire Europe via COMTEX) -- HATFIELD,
England, July 29, 2013 /PRNewswire/ --
Partnership deal secured with Yiaco for Kuwait distribution
Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) today announces
its partnership with Kuwait's leading pharmaceutical marketing agency, Yiaco
Medical Company, for the distribution of Halaven(R) (eribulin), for the
treatment of patients with locally advanced or metastatic breast cancer, who
have progressed after at least two chemotherapeutic regimens for advanced
disease.
Commenting on the availability of eribulin in Kuwait, Toshitaka Asano, Vice
President Market Development Business Unit EMEA, said: "The distribution of
Halaven in Kuwait is part of Eisai's wider strategy of establishing a solid
foundation in the EMEA region. We recognise Kuwait as a strong and stable market
in the region which has a rapidly growing population with very specific
healthcare needs. Our valued partnership with Yiaco Medical Company will mean
people can receive rapid access to innovative treatments not previously
available to them."
Kuwait is recognised as one of the best-regulated pharmaceutical markets of the
Gulf Cooperation Council (GCC) and remains the second most attractive
pharmaceutical market in the region according to the latest Business Monitor
International (BMI) Risk / Reward Ratings (RRR) analysis.[1] Continued market
growth is anticipated over the next five years, buoyed up by both a high birth
rate and an expanding population, offering the industry a relatively stable
environment in which to operate.[1]
"As the market-leading pharmaceutical distributor in Kuwait, we are excited
about the opportunity to work in partnership with Eisai to distribute Halaven in
this region," said Tareq Alryan, Assistant CEO, Pharma and Business Development,
at Yiaco Medical Company. "Our unrivalled market knowledge and reputation in the
region allows us to support Eisai in launching Halaven in Kuwait, whilst at the
same time addressing the health needs of patients and their families in Kuwait."
Eribulin is now commercially available in Kuwait and received the full
registration in October 2012.
As part of Eisai's globalisation strategy set out in its mid-term strategic plan
in 2011 "HAYABUSA", the company seeks to expand its global presence by 2015 in
an effort to achieve its objective of making contributions to more than 500
million patients worldwide. Since its launch in the European Union in March
2011, eribulin is now widely available worldwide.
ENDS
Notes to Editors
About Eisai's Commitment to Improving Global Access to Medicines
Today, it is estimated that some 2.7 billion* people around the world live on
US$ 2 or less per day. Most of these 2.7 billion people do not have access to
essential health care and treatment despite the availability of effective
medicines. This is an international challenge that needs to be solved through
collaborations among governments, international organisations such as the WHO,
non-governmental organisations and pharmaceutical companies.
In line with its human health care (hhc) mission, Eisai is committed to
improving global access to medicines over the medium-to-long term through
partnership strategies that involve working with governments, international
organisations, private entities and non-profit organisations. Specifically, the
company has developed and is implementing a five-target approach to improve
access to medicines worldwide. The five key components are: product creations,
strategic solutions, capacity building, quality innovation, and long-term
investment.
For further information on Eisai's Access to Medicines initiatives, please visit
the Access to Medicines page on the Eisai Global
website:http://www.eisai.com/company/atm/index.html
* Source: World Bank (2005)
About Eisai
Eisai is one of the world's leading research and development (R&D) based
pharmaceutical companies and we define our corporate mission as "giving first
thought to patients and their families and to increasing the benefits health
care provides," which we call human health care (hhc).
Eisai concentrates its R&D activities in three key areas:
- Oncology including: anticancer therapies; tumour regression, tumour
suppression, antibodies, etc
- Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight loss
- Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
arthritis, psoriasis, and inflammatory bowel disease
With operations in the U.S., Asia, Europe and its domestic home market of Japan,
Eisai employs more than 10,000 people worldwide. From its Knowledge Centre in
Hatfield, UK, Eisai has recently expanded its business operations to include
Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA has sales
and marketing operations in over 20 markets, including the United Kingdom,
France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark,
Finland, Norway, Portugal, Czech Republic, Slovakia, the Netherlands, Belgium,
the Middle East and Russia.
For further information please visit: http://www.eisai.co.uk
About Yiaco
Yiaco Medical Company was established in the year 1953 as a sole marketing agent
for many multinational research-based pharmaceutical manufacturers. Yiaco
quickly grew with the boom in Kuwait's own national growth and development,
diversifying and expanding into other healthcare services such as Medical
Equipment, Hospital supplies and Dental equipment & materials. Through its many
years of operation and experience in the medical field, Yiaco's reputation of
excellence precedes its name. A name that has come to mean undisputed market
leadership in the area of medical care, unparalleled sales and services, as well
as innovative state-of-the-art technology for the medical and healthcare fields.
Yiaco is fully committed to the modern healthcare system in Kuwait and abroad;
and through this commitment, it has earned the privilege of delivering
intelligent and economic solutions to the medical profession and the public.
This commitment is not only evident through its ability to equip entire
hospitals and research centers from the ground up, but in its solid financial
holdings and a proud family of employees.
1. Business Monitor International: Industry Risk / Reward Ratings - Kuwait - Q2,
2013
Date of preparation: July 2013
Job Code: Halaven-UK0146
CONTACT: CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson / CharlotteAndrews,
+44(0)7908 314 155 / +44(0)7947 231 513,Cressida_Robson@eisai.net,
Charlotte_Andrews@eisai.net ; Tonic LifeCommunications, Siobhan Reilly / April
Kenneally, +44(0)207 798 9999 / +44(0) 207 798 9263, siobhan.reilly@toniclc.com
, april.kenneally@toniclc.com; For further information on Yiaco Medical Company
in Kuwait, pleasecontact: Tareq Alryan - Assistant CEO, Pharma and Business
Development,Yiaco , +965 222 460 31, agm@yiacokuwait.com. For further
information onYiaco Medical Company in Kuwait, please contact: Tareq Alryan -
AssistantCEO, Pharma and Business Development, Yiaco,
+965-222-460-31,agm@yiacokuwait.com
Copyright (C) 2013 PR Newswire Europe
-0-
SUBJECT CODE: PDT
Topic
BIO
Topic
HEA
Topic
MTC
Topic
United Kingdom
Iran
Iraq
Israel
Jordan
Kuwait
Lebanon
Saudi Arabia
Syria
Bahrain
Palestine
Qatar
Yemen
Oman
United Arab Emirates
News for 'ESALY' - (Eisai Announces Availability of Halaven(R) (eribulin) in Kuwait)
HATFIELD, England, Jul 28, 2013 (PR Newswire Europe via COMTEX) -- HATFIELD,
England, July 29, 2013 /PRNewswire/ --
Partnership deal secured with Yiaco for Kuwait distribution
Eisai EMEA (Europe, the Middle East, Africa, Russia and Oceania) today announces
its partnership with Kuwait's leading pharmaceutical marketing agency, Yiaco
Medical Company, for the distribution of Halaven(R) (eribulin), for the
treatment of patients with locally advanced or metastatic breast cancer, who
have progressed after at least two chemotherapeutic regimens for advanced
disease.
Commenting on the availability of eribulin in Kuwait, Toshitaka Asano, Vice
President Market Development Business Unit EMEA, said: "The distribution of
Halaven in Kuwait is part of Eisai's wider strategy of establishing a solid
foundation in the EMEA region. We recognise Kuwait as a strong and stable market
in the region which has a rapidly growing population with very specific
healthcare needs. Our valued partnership with Yiaco Medical Company will mean
people can receive rapid access to innovative treatments not previously
available to them."
Kuwait is recognised as one of the best-regulated pharmaceutical markets of the
Gulf Cooperation Council (GCC) and remains the second most attractive
pharmaceutical market in the region according to the latest Business Monitor
International (BMI) Risk / Reward Ratings (RRR) analysis.[1] Continued market
growth is anticipated over the next five years, buoyed up by both a high birth
rate and an expanding population, offering the industry a relatively stable
environment in which to operate.[1]
"As the market-leading pharmaceutical distributor in Kuwait, we are excited
about the opportunity to work in partnership with Eisai to distribute Halaven in
this region," said Tareq Alryan, Assistant CEO, Pharma and Business Development,
at Yiaco Medical Company. "Our unrivalled market knowledge and reputation in the
region allows us to support Eisai in launching Halaven in Kuwait, whilst at the
same time addressing the health needs of patients and their families in Kuwait."
Eribulin is now commercially available in Kuwait and received the full
registration in October 2012.
As part of Eisai's globalisation strategy set out in its mid-term strategic plan
in 2011 "HAYABUSA", the company seeks to expand its global presence by 2015 in
an effort to achieve its objective of making contributions to more than 500
million patients worldwide. Since its launch in the European Union in March
2011, eribulin is now widely available worldwide.
ENDS
Notes to Editors
About Eisai's Commitment to Improving Global Access to Medicines
Today, it is estimated that some 2.7 billion* people around the world live on
US$ 2 or less per day. Most of these 2.7 billion people do not have access to
essential health care and treatment despite the availability of effective
medicines. This is an international challenge that needs to be solved through
collaborations among governments, international organisations such as the WHO,
non-governmental organisations and pharmaceutical companies.
In line with its human health care (hhc) mission, Eisai is committed to
improving global access to medicines over the medium-to-long term through
partnership strategies that involve working with governments, international
organisations, private entities and non-profit organisations. Specifically, the
company has developed and is implementing a five-target approach to improve
access to medicines worldwide. The five key components are: product creations,
strategic solutions, capacity building, quality innovation, and long-term
investment.
For further information on Eisai's Access to Medicines initiatives, please visit
the Access to Medicines page on the Eisai Global
website:http://www.eisai.com/company/atm/index.html
* Source: World Bank (2005)
About Eisai
Eisai is one of the world's leading research and development (R&D) based
pharmaceutical companies and we define our corporate mission as "giving first
thought to patients and their families and to increasing the benefits health
care provides," which we call human health care (hhc).
Eisai concentrates its R&D activities in three key areas:
- Oncology including: anticancer therapies; tumour regression, tumour
suppression, antibodies, etc
- Neuroscience, including: Alzheimer's disease, epilepsy, pain and weight loss
- Vascular/Immunological reaction including: thrombocytopenia, rheumatoid
arthritis, psoriasis, and inflammatory bowel disease
With operations in the U.S., Asia, Europe and its domestic home market of Japan,
Eisai employs more than 10,000 people worldwide. From its Knowledge Centre in
Hatfield, UK, Eisai has recently expanded its business operations to include
Europe, the Middle East, Africa, Russia and Oceania (EMEA). Eisai EMEA has sales
and marketing operations in over 20 markets, including the United Kingdom,
France, Germany, Italy, Spain, Switzerland, Sweden, Ireland, Austria, Denmark,
Finland, Norway, Portugal, Czech Republic, Slovakia, the Netherlands, Belgium,
the Middle East and Russia.
For further information please visit: http://www.eisai.co.uk
About Yiaco
Yiaco Medical Company was established in the year 1953 as a sole marketing agent
for many multinational research-based pharmaceutical manufacturers. Yiaco
quickly grew with the boom in Kuwait's own national growth and development,
diversifying and expanding into other healthcare services such as Medical
Equipment, Hospital supplies and Dental equipment & materials. Through its many
years of operation and experience in the medical field, Yiaco's reputation of
excellence precedes its name. A name that has come to mean undisputed market
leadership in the area of medical care, unparalleled sales and services, as well
as innovative state-of-the-art technology for the medical and healthcare fields.
Yiaco is fully committed to the modern healthcare system in Kuwait and abroad;
and through this commitment, it has earned the privilege of delivering
intelligent and economic solutions to the medical profession and the public.
This commitment is not only evident through its ability to equip entire
hospitals and research centers from the ground up, but in its solid financial
holdings and a proud family of employees.
1. Business Monitor International: Industry Risk / Reward Ratings - Kuwait - Q2,
2013
Date of preparation: July 2013
Job Code: Halaven-UK0146
CONTACT: CONTACT: Media Enquiries: Eisai Europe Ltd, Cressida Robson / CharlotteAndrews,
+44(0)7908 314 155 / +44(0)7947 231 513,Cressida_Robson@eisai.net,
Charlotte_Andrews@eisai.net ; Tonic LifeCommunications, Siobhan Reilly / April
Kenneally, +44(0)207 798 9999 / +44(0) 207 798 9263, siobhan.reilly@toniclc.com
, april.kenneally@toniclc.com; For further information on Yiaco Medical Company
in Kuwait, pleasecontact: Tareq Alryan - Assistant CEO, Pharma and Business
Development,Yiaco , +965 222 460 31, agm@yiacokuwait.com. For further
information onYiaco Medical Company in Kuwait, please contact: Tareq Alryan -
AssistantCEO, Pharma and Business Development, Yiaco,
+965-222-460-31,agm@yiacokuwait.com
Copyright (C) 2013 PR Newswire Europe
-0-
SUBJECT CODE: PDT
Topic
BIO
Topic
HEA
Topic
MTC
Topic
United Kingdom
Iran
Iraq
Israel
Jordan
Kuwait
Lebanon
Saudi Arabia
Syria
Bahrain
Palestine
Qatar
Yemen
Oman
United Arab Emirates
we can read all of the reports and opinions
until the end of time, but i truly believe one
of the big pharma's are going to buy -arna-/
-esaly- out. they are not going to let these
little companies get all the profit from this
class of drug market. they are going to bite
the bullet and give up. they will not risk the
chance on the other potential players